5591 results
Refine Your Search
A phase 2 study of RVU120, a novel CDK8 inhibitor, in combination with venetoclax in patients with AML
In August , TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of SEL120 in Patients With Acute Myeloid Leu…
A phase 1 study of DR-0201, a bispecific myeloid engager, in patients with B-NHL
In November , LLS made an equity investment in Dren Bio to "Support Clinical Development of the Program for Rare Leukemia & Lymphoma Indications Incl…
Developing Novel Immunotherapies for Challenging Lymphomas
This team science program from Washington University will develop new immunotherapy treatments for patients with hard to treat or incurable lymphomas.…
Memory-like NK cells after hematopoietic cell transplant to eradicate measurable residual disease
Relapse in patients with acute myeloid leukemia (AML) after hematopoietic cell transplant (HCT) is associated with extremely poor prognosis and thus r…
Financial assistance
Financial assistance programs from Blood Cancer United are making costly blood cancer care more accessible to patients.
Financial Support
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engine…
Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast
Black and Hispanic individuals diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. Using an innovative data source, this s…
Raymond Mailhot
Despite Hodgkin lymphoma’s (HL) favorable prognosis, Black and Hispanic patients have worse survival rates compared to White patients. Insurance statu…
H. Irene Su, MD
Dr. Su is Professor of Obstetrics, Gynecology and Reproductive Science in the Division of Reproductive Endocrinology and Infertility at the University…
Impact of State Health Insurance Mandates on Affordability and Utilization of Fertility Preservation in Adolescent and Young Adults with Blood Cancers
Fertility preservation (FP) treatments can prevent infertility caused by blood cancer. However, FP costs are high, and these services are typically no…
Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO Study
In collaboration with oncology practice sites, this study will implement a intervention trial to test the effectiveness of two community oncology s…
Epigenetic heterogeneity in age-related clonal hematopoiesis and acute myeloid leukemia
Our focus is to unravel how clonal hematopoiesis (CH) progresses to leukemia. We will investigate how epigenetic heterogeneity affects Tet2-mutant hem…
A randomized clinical trial of oral vitamin A to reduce chronic graft versus host disease in BMT
Vitamin A is safe, well tolerated and positively affects gut immune health. Graft versus host disease (GVHD) is a complication of bone marrow transpl…
Patient-Reported Outcomes and Survivorship in Histiocytic Neoplasms
Advances in the treatment of Langerhans cell histiocytosis and disease have led to a growing survivor population; however, there is a lack of informa…
Novel Immunotherapy Combinations in Relapsed, Refractory Mantle Cell Lymphoma
We are evaluating two parallel clinical trials with synergistic immunotherapies in mantle cell lymphoma (MCL), including ) tafasitamab and lenalidomid…
Targeting SF3B1 splicing factor mutant myeloid malignancies through dependency on GPATCH8
Mutations in RNA splicing factors, particularly those involving the core splicing factor SF3B1 are amongst the most common mutations found in myeloid …
Improving outcomes with immune therapies for multiple myeloma
The primary focus of research is to better understand mechanisms of resistance to immunotherapies and design treatment approaches to improve outcomes.…
Novel targeted therapies for acute myeloid leukaemia and multiple myeloma
Outcomes for acute myeloid leukemia (AML) and multiple myeloma (MM) patients remain inadequate and new treatment options to combat resistance against …
Multiple Myeloma Support from the Microenvironment: Bone Marrow Adipocytes and the Fatty Acid Binding Proteins
Our project’s goal is to change how multiple myeloma is understood and treated by interrogating a novel part of the cellular “soil” (the bone marrow a…
MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)
The MULTIPLY is a large project aimed at characterization of a variety of clinical predictors, both baseline and at relapse through three interconnec…
Martin Dreyling
Martin Dreyling is Professor of Medicine and head of the lymphoma programme at the Department of Medicine III, LMU Hospital Munich. He studied at the …
Limited-duration bispecific antibody therapy for multiple myeloma
Bispecific antibodies are a new, highly effective immunotherapy for multiple myeloma. Most bispecific antibody therapies have been tested as continuou…
Prevention of antigen escape by modulation of off-target tumor killing in T cells
mediated therapies are all impeded by the same cause- tumoral antigen (Ag) escape: rare Ag– cells in tumors survive the initial attack and lead to rel…
Shazia Nakhoda
Dr. Nakhoda is a in the department of hematology/oncology at Fox Chase Cancer Center. She serves as steering committee member for the Leukemia & Lymp…
Role of ID2 in mature T-cell lymphoma
Overexpression of ID2 is a recurrent event in mature lymphoma (TCL), and its significance is yet to be established. We will use a multidisciplinary a…